
Sight sciences
Sight Sciences is an ophthalmic medical device company specializing in the development and commercialization of innovative surgical and nonsurgical technologies for treating common eye diseases.
Sight sciences Overview
Sight sciences Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
IPO | 7/15/2021 | ||||
Series F | 12/9/2020 | ||||
Series E | 3/18/2020 | ||||
Series D | 8/26/2019 | ||||
Series C | 5/31/2018 | ||||
Series B | 10/29/2015 |
Sight sciences 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Sight sciences Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Sight sciences News
Sight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 20,734 Shares
MarketBeatOctober 19, 2024
Sight sciences' chief commercial officer sells shares worth $244,878
Investing.comOctober 19, 2024
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
Yahoo FinanceOctober 17, 2024
Renaissance Technologies LLC Has $461,000 Stake in Sight Sciences, Inc. (NASDAQ:SGHT)
MarketBeatOctober 11, 2024
Sight Sciences shares reiterate Buy rating from Lake Street on growth potential By Investing.com
Investing.comOctober 5, 2024
Sight Sciences shares reiterate Buy rating from Lake Street on growth potential By Investing.com
Investing.com UKOctober 4, 2024
Sight Sciences CEO Paul Badawi sells shares worth over $76k
Investing.comOctober 4, 2024
Sight Sciences COO sells shares worth over $20,000
Investing.comOctober 4, 2024